Compare CVS Health Corp (CVS) vs Meta Platforms Inc (META) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Meta Platforms Inc — how do they compare? CVS Health Corp trades at $104.32 (market cap $135.48B), while Meta Platforms Inc trades at $662.27 (market cap $1.68T). The key difference: Meta Platforms Inc is far larger — about 12.4× CVS Health Corp's market cap, and CVS Health Corp pays the higher dividend (2.51%). Which is the better fit depends on your goals.
| CVS | META | |
|---|---|---|
Market Cap | $135.48B | $1.68T |
Sector | Health | Media |
52-Week High | $106.18 | $790.00 |
52-Week Low | $58.75 | $525.72 |
Enterprise Value | $202.02B | $1.68T |
Dividend Yield | 2.51% | 0.32% |
Volume | — | 24,093,972 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $105.9, up 1.68% recently, with a bullish technical signal and strong analyst support (84.6% buy ratings). The company has beaten earnings estimates for three consecutive quarters, including Q1 2026 EPS of $2.57 versus $2.18 expected. Revenue growth remains robust, reaching $402.07B in 2025, though net margins are thin at 0.72%. Recent news highlights a settlement with the FTC advancing prescription drug affordability initiatives.
The outlook is positive given earnings momentum and strategic positioning in healthcare services, but risks include regulatory pressures and margin compression. The consensus price target of $110.62 suggests modest upside from current levels, supported by dividend payments and institutional confidence.
Meta Platforms (META) trades at $656.73, down 1.86% on the day, amid strong technical and fundamental momentum. The stock maintains a bullish technical signal with key support at $653 and resistance at $663. Recent earnings beats, including Q1 2026 EPS of $10.44 versus $6.70 expected, highlight robust profitability with a 32.84% net margin. The launch of Muse Spark AI and a $21 billion deal with CoreWeave underscore strategic growth initiatives, though legal challenges persist.
Outlook remains positive with a consensus price target of $815.44, implying 24% upside. Strengths include dominant market position, AI innovation, and strong cash flow. Risks involve regulatory lawsuits, high capital expenditure, and competitive pressures. Institutional sentiment is bullish with 79% buy ratings, but investors should monitor litigation outcomes and AI monetization progress.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →
